Capecitabine: fulfilling the promise of oral chemotherapy

Bibliography

• LIU G, FRANSSEN E, FITCH MI, WARNER E: Patient preferences for oral versus intravenous palliative chemotherapy. Clin. Oncol. (1997) 15(1):110–115.
   Web of Science ®Google Scholar
• VAN CUTSEM E, SORENSEN J, CASSIDY J et al.: International Phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc. Am. Soc. Clin. Oncol. (2001) 20: 131a. Abstract 522.
   Google Scholar
• MIWA M, URA M, NISHIDA M et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer (1998) 34(8):1274–1281.
   PubMed Web of Science ®Google Scholar
• SCHULLER J, CASSIDY J, DUMONT E et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. (2000) 45:291–297.
   PubMed Web of Science ®Google Scholar
• TAKEBAYASHI Y, AKIYAMA S-I, AKIBAS et al.: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. Natl. Cancer Inst. (1996) 88(16):1110–1117.
   Google Scholar
• BUDMAN DR, MEROPOL NJ, REIGNER B et al.: Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.j Clin. Oncol. (1998) 16(5):1795–1802.
   Google Scholar
• MACKEAN M, PLANTING A, TWELVES C et al.: Phase I and pharma-cologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. (1998) 16(9):2977–2985.
   PubMed Web of Science ®Google Scholar
• CASSIDY J, TWELVES C, CAMERON D et al.: Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother. Pharmacol. (1999) 44:453–460.
   PubMed Web of Science ®Google Scholar
• REIGNER B, VERVVEIJ J, DIRIX L et al.: Effect of food on the pharmacolkinetics of capecitabine and its metabolits following oral administration in cancer patients. Clin. Cancer Res. (1998) 4(4):941–948.
   PubMed Web of Science ®Google Scholar
• REIGNER B, CLIVE S, CASSIDY J et al: Influence of the antacid Maalox on the pharmacolkinetics of capecitabine in cancer patients. Cancer Chemother: Pharmacol. (1999) 43:309–315.
   PubMed Web of Science ®Google Scholar
• TWELVES C, GLYNNE-JONES R, CASSIDY J et al.: Effect of hepatic dysfunction due to liver metastases on the pharmacolkinetics of capecitabine and its metabolites. Clin. Cancer Res. (1999) 5(7):1696–1702.
   PubMed Web of Science ®Google Scholar
• POOLE C, GARDINER J, TWELVES C et al.: Effect of renal impairment on the pharmacolkinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother. Pharmacol. (2002) 49:225–234.
   PubMed Web of Science ®Google Scholar
• CASSIDY J, TWELVES C, VAN CUTSEM E et al.: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol. (2002) 13:566–575.
   Google Scholar
• CASSIDY J, DIRIX L, BISSETT D et al: A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin. Cancer Res. (1998) 4(11):2755–2761.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, FINDLAY M, OSTERWALDER B et al.: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study." Clin. Oncol. (2000) 18(6):1337–1345.
   Google Scholar
• ROUGIER P, VAN CUTSEM E, BAJETTA E et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluourouracil failure with metastatic colo-rectal cancer. Lancet (1998) 352:1407–1412.
   PubMed Web of Science ®Google Scholar
• HOFF P, ABBRUZZESE JL, MEDGYESY D, THOMAS M, CARTER S: A Phase II study of Xeloda (capecitabine) in patients with metastatic colorectal cancer demonstrating progression on 5-FU therapy. Proc. Am. Soc. Clin. Oncol. (2000) 19:256a. Abstract 993.
   Google Scholar
• HOFF PM, ANSARI R, BATIST G et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. I Clin. Oncol. (2001)19(8):2282–2292.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, TWELVES C, CASSIDY J et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. " Clin. Oncol. (2001) 19(21):4097–4106.
   Google Scholar
• SWAIN SM, LIPPMAN ME, EGAN EF, DRAKE JC, STEINBERG SM, ALLEGRA CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. (1989) 7(7):890–899.
   PubMedGoogle Scholar
• CAMERON DA, GABRA H, LEONARD RCF: Continuous 5-fluourouracil in the treatment of breast cancer. Br. J. Cancer (1994) 70:120–124.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY JA, BLUM J, MOISEYENKO V et al.: Randomized, open-label, Phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann. Oncol. (2001) 12:1247–1254.
   Google Scholar
• BLUM JL, JONES SE, BUZDAR AU et al.: Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. Clin. Oncol. (1999) 17(2):485–493.
   Google Scholar
• BLUM JL, DIERAS V, LORUSSO PM et al.: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer (2001) 92(7):1759–1768.
   PubMed Web of Science ®Google Scholar
• SUNDRARM S, LANCASTER D, SILVA J et al: Oral capecitabine is an acitve and well tolerated primary palliative treatment in patients with metastatic breast cancer who progress after high dose chemotherapy and autologous stem cell support. Proc. Am. Soc. Clin. Oncol. (2000) 19:58a. Abstract 223.
   Google Scholar
• JAKOB A, SCHUP M, KNOP S, FRINGS S, FLOEMER F, KANZ L: A Phase II study of capecitabine in patients, who relapsed after high dose chemotherapy followed by peripheral blood stem cell transplantation for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:556. Abstract 1966.
   Google Scholar
• WONG ZW, WONG KK, CHEW Let al. Capecitabine as an oral chemotherapeutic agent in the treatment of refractory meta-static breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2000) 19:120a. Abstract 466.
   Google Scholar
• CERVANTES G, TORRECILLAS, ERAZO AA et al.: Capecitabine (Xeloda) as treatment after failure to taxanes for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:121a. Abstract 469.
   Google Scholar
• THUSS-PATIENCE PC, VON MINCKWITZ G, LUCK HJ et al.: Capecitabine: a new standard in metastatic breast cancer recurring after anthracycline and taxane-containing chemotherapy? Results of a multicenter Phase II Trial. Proc. Am. Soc. Clin. Oncol. (2001) 20:6613. Abstract 2012.
   Google Scholar
• KUSAMA M, SANO M, IKEDA T, SON00 H, TAKASHIMA S: A Phase II study of Xeloda (capecitabine) in patients with advanced/metastatic breast carcinoma - The Cooperative Study Group of Capecitabine for Breast Carcinoma. Proc. Am. Soc. Clin. Oncol. (2001) 20:4413. Abstract 1924.
   Google Scholar
• WATANABE T, KATSUMATA N, SASAKI Y et al.: A multicenter Phase II trial of Xeloda (capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:61b. Abstract 1991.
   Google Scholar
• CARTWRIGHT TH, COHN A, VARKEYJA et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. (2002) 20(2):160–164.
   PubMedGoogle Scholar
• LOZANO RD, PATT YZ, HASSAN MM et al: Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangio-carcinoma, and gall bladder cancer). Proc. Am. Soc. Clin. Oncol. (2000) 19:264a. Abstract 1025.
   Google Scholar
• KOIZUMI W, TAGUCHI T: A Phase II study of capecitabine (Xeloda) in patients with advanced/metastatic gastric carcinoma. Proc. Am. Soc. Clin. Oncol. (2001) 20:1426. Abstract 2320.
   Google Scholar
• WENZEL CC, SCHMIDINGER MP, LOCKER GJ et al: Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy - The Vienna Experience. Proc. Am. Soc. Clin. Oncol. (2001) 20:196a. Abstract 782.
   Google Scholar
• OEVERMANN K, BUER J, HOFFMANN R et al.: Capecitabine in the treatment of metastatic renal cell carcinoma. Br. I Cancer (2000) 83(5):583–587.
   PubMedGoogle Scholar
• ABUSHULLAIH S, SAAD E, HOFF PM: Characterizing Hand-Foot Syndrome (HFS) caused by capecitabine. Proc. Am. Soc. Clin. Oncol. (2000) 19:16313. Abstract 2403.
   Google Scholar
• LAUMAN MK, MORTIMER J: Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine. Proc. Am. Soc. Clin. Oncol. (2001) 20:392a. Abstract 1565.
   Google Scholar
• O'SHAUGHNESSY J, BLUM J: A Retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc. Am. Soc. Clin. Oncol. (2000) 19:104a. Abstract 400.
   Google Scholar
• SAWADA N, ISHIKAWA T, FUKASE Y et al.: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenograft. Clin. Cancer Res. (1998) 4:1013–1019.
   PubMed Web of Science ®Google Scholar
• VILLALONA-CALERO MA, WEISS GR, BURRIS HA et al.: Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J. Clin. Oncol. (1999) 17(6):1915–1925.
   PubMed Web of Science ®Google Scholar
• VILLALONA-CALERO MA, BLUM JL, JONES SE et al: A Phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann. Oncol. (2001) 12:605–614.
   PubMedGoogle Scholar
• ELZA-BROWN K, DEES EC, WOLFF AC,CARDUCCI MA, DONEHOWER RC:A Phase I study of capecitabine and weekly paclitaxel in advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2000) 19:237a. Abstract 921J.
   Google Scholar
• MEZA LA, AMIN B, HORSEY M, PETRALIA SA, SZATROWSKI TP, GRADISHAR WJ: A Phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Omni (2001) 20:706. Abstract 2029.
   Google Scholar
• PRONK L, VASEY AP, SPARREBOOM A et al.: A Phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br. Cancer(2000) 83(1):22–29.
   Google Scholar
• O'SHAUGHNESSY J, VUKELJA S, MOISEYENKO V et al.: Results of a large, Phase III trial of Xeloda/Taxotere combination therapy versus Taxotere monotherapy in patients with metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium. 6–9 December (2000). Abstract 381.
   Google Scholar
• SCHILSKY RL, BERTUCCI D, VOGELZANG NJ, KINDLER HL, RATAIN MJ: Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. Clin. Omni. (2002) 20(2):582–587.
   PubMedGoogle Scholar
• SALTZ LB, COX JV, BLANKE C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl.' Med. (2001) 343(12):905–914.
   Google Scholar
• CASSATA A, STANI SC, ALU M et al.: Ongoing Phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Omni (2001) 20:144a. Abstract 573.
   Google Scholar
• TEWES M, SCHLEUCHER N, ACHTERRATH W et al.: Extended Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line therapy in metastatic colorectal cancer. Proc Am Soc Cancer Res (2001) 42:698. Abstract 3752.
   Google Scholar
• DIAZ-RUBIO E, EVANS J, TABERNERO J et al.: Phase I Study of capecitabine in combination with oxaliplatin in patients with advanced or metastatic solid tumors. Proc. Am. Soc. Clin. Omni (2000) 19:198a. Abstract 772.
   Google Scholar
• DESANTIS S, ZEULI M, DI COSTANZO F et al.: Oxaliplatin and capecitabine in advanced colorectal cancer: a dose-finding trial. Proc. Am. Soc. Clin. Omni (2001) 20:141a. Abstract 559.
   Google Scholar
• THOMAS R, QUINN M, WILSON R et al.: A Phase I trial of capecitabine (CAPE) & oxaliplatin (OHP). Proc. Am. Soc. Clin. Omni (2001) 20:133a. Abstract 530.
   Google Scholar
• BORNER MM, MUELLER S, ROTH A et al.: Phase II study of capecitabine (CAP) + oxaliplatin (OXA) in first line and second line treatment of advanced or metastatic colorectal cancer (ACC). Proc. Am. Soc. Clin. Omni (2001) 20:137a. Abstract 546.
   Google Scholar
• TWELVES C et al.: Capecitabine in combination with oxaliplatin as first-line therapy for patients with advanced or metastatic colorectal cancer: preliminary results of an international multicenter Phase II study. European Cancer Conference 11, Lisbon Portugal 21–25 October (2001). Abstract 20.
   Google Scholar
• AKHTAR SU, MATHEW P, LIN J, CHAN R, ZWISCHENBERGERJ, JONES DV, Jr: Phase II trial of capecitabine and carboplatin in patients with newly diagnosed, advanced non-small cell carcinoma of the lung (NSCLC). Proc. Am. Soc. Clin. Omni. (2001) 20:2786. Abstract 2862.
   Google Scholar
• KIM TW, AHN JH, LEE JH et al: A PhaseII Trial of Capecitabine (X) and Cisplatin (P) in Previously Untreated Advanced Gastric Cancer (AGC). Proc. Am. Soc. Clin. Omni. (2001) 20:166a. Abstract 662.
   Google Scholar
• WELT A, BORQUEZ D, OBERHOFF C et al.: Phase I study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Proc. Am. Soc. Clin. Omni (2001) 20:586. Abstract 1979.
   Google Scholar
• KIMMEL KA, KINDLER HL, JANISCH L, OLSON S, GROVE W, RATAIN MJ: Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Omni. (2001) 20:87a. Abstract 345.
   Google Scholar
• HOLDEN SN, ECKHARDT SG, FISHER S et al.: A Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies. Proc. Am. Soc. Clin. Omni (2001) 20:80a. Abstract 316.
   Google Scholar
• BYFIELD JE: 5-0uorouracil radiation sensitization-a brief review. Investig. New Drugs. (1989) 11:111–116.
   Google Scholar
• SAINI A, CUNNINGHAM D, NORMAN AR et al.: Multicentre randomized trial of protracted venous infusion (PVI) 5 FU compared to 5 FU/Folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer. Proc. Am. Soc. Clin. Omni. (2000) 19:240a. Abstract 928.
   Google Scholar
• SAWADA N, ISHIKAWA T, SEKIGUCHI F et al: X-Ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin. Cancer Res. (1999) 5(10):2948–2953.
   PubMed Web of Science ®Google Scholar
• DUNST J, REESE S, FRINGS S et al: Phase I study of capecitabine combined with radiotherapy for locally advanced potentially operable rectal cancer. Proc. Am. Soc. Clin. Omni (2001) 20:149a. Abstract 592.
   Google Scholar
• MATHIJSSEN RHJ, VERWEIJ J, DE JONGE MJA, NOOTER K, STOTER G, SPARREBOOM A: Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. Clin. Omni (2002) 20(1):81–87.
   PubMedGoogle Scholar
• SAWYER M, RATAIN MJ: Body Surface area as a determinant of pharmacokinetics and drug dosing. Investig. New Drugs (2001) 19:171–177.
   PubMed Web of Science ®Google Scholar